Exhibit 10.3

For immediate release

               COMPETITIVE TECHNOLOGIES ENTERS INTO $8.0 MILLION
                        COMMON STOCK PURCHASE AGREEMENT

       PROCEEDS WILL BE USED TO BRIDGE TO PAIN MANAGEMENT MEDICAL DEVICE
                               COMMERCIALIZATION

FAIRFIELD,  CT  (AUGUST  6,  2008)  - COMPETITIVE TECHNOLOGIES, INC. (NYSE AMEX:
CTT),  announced  today  that  it  has entered into an $8.0 million common stock
purchase  agreement  with  Fusion  Capital  Fund  II,  LLC,  a  Chicago-based
institutional  investor.  Fusion  Capital  has  been  an  investor  in CTT since
February  2004 and has previously provided approximately $7.0 million in funding
to  the  company.  CTT may sell up to $8.0 million of its common stock to Fusion
Capital  from  time  to  time  over  a  25-month period after the Securities and
Exchange  Commission  has declared effective a registration statement related to
the  transaction.

"This  arrangement  will  provide  CTT  with needed bridge funding until we have
increased  revenue  from our exciting pain therapy medical device," said John B.
Nano, CTT's Chairman, President and CEO. "CTT is very pleased to again work with
Fusion  Capital."

CTT recently signed an agreement with Innovative Medical Therapies, Inc (IMT)
granting them exclusive distribution rights to CTT's pain therapy medical device
in the United States and related territories excluding selected Federal
agencies. The contract provides for minimum monthly cash payments to CTT
totaling over $1 million for the first five months. These minimum monthly
payments increase throughout the term of the agreement with the fourth year
minimum payments reaching $9 million and eighth year minimum payments of $21
million dollars. Seven sales agreements for the pain therapy medical device are
now in place for 42 countries around the world accounting for over 50% of the
world's population. CTT has exclusive worldwide rights to this device. The
device has U.S. FDA 510(k) clearance for U.S. sales, as well as Medical Device
CE certification from the E.U. allowing sales throughout Europe and several
other countries. Fusion Capital funding will help provide the necessary
resources for the global distribution ramp-up.

CTT recently announced that the U.S. Patent and Trademark Office's Board of
Patent Appeals and Interferences (BPAI) has upheld its homocysteine patent
re-examination. The contested license fees at issue in this case are estimated
to be worth over $5 million, including interest and penalties The patent was
re-examined pursuant to the lawsuit brought in the Colorado U.S. District Court
in 2005 by CTT to protect its patent rights and those of its clients and
licensees from unlicensed use of the technology by defendants Carolina Liquid
Chemistries Corporation, General Atomics, and Catch Inc. CTT's patent rights
were previously upheld by the U.S.Supreme Court and U.S.District Courts.

Under  the  agreement,  CTT  has the right to sell shares of its common stock to
Fusion  Capital  from  time to time in amounts between $75,000 and $2.0 million,
depending  on  certain  conditions,  up  to  $8.0  million in the aggregate. The
purchase  price  of  the shares will be based on the prevailing market prices of
CTT's  shares  at  the  time  of  sales without any fixed discount, and CTT will
control  the  timing  and amount of any sales of shares to Fusion Capital. There
are  no  negative  covenants,  restrictions  on  future financings, penalties or
liquidated  damages  in  the  agreement.  A  more  detailed  description  of the
agreement  is set forth in CTT's current report on Form 8-K filed today with the
SEC.

The homocysteine technology is one of CTT's outstanding technologies. Additional
technologies that generate revenue include CTT's pain therapy medical device,
bone biomaterial, melanocortins, MPEG-4 image coding and compression, and
structural crack detection paint. CTT's management team is focused on creating
value from technologies and increasing shareholder value.


<PAGE>
ABOUT  FUSION  CAPITAL  II,  LLC

Fusion  Capital  Fund  II,  LLC  is  an institutional investor based in Chicago,
Illinois  with  a  fundamental  investment approach. Fusion Capital invests in a
wide  range  of  companies  and industries emphasizing life sciences, cleantech,
energy  and  technology  companies. Its investments range from special situation
financing  to  long-term  strategic  capital.
ABOUT COMPETITIVE TECHNOLOGIES, INC.

Competitive Technologies, established in 1968, provides distribution, patent and
technology transfer, sales and licensing services focused on the needs of its
customers and matching those requirements with commercially viable product or
technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
                ------------------------------------
and physical sciences developed by universities, companies and inventors. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: www.competitivetech.net
                                               -----------------------

Statements made about our future expectations are forward-looking statements and
subject to risks and uncertainties as described in our most recent Annual Report
on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28,
2008, and other filings with the SEC, and are subject to change at any time. Our
actual results could differ materially from these forward-looking statements. We
undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:  Johnnie D. Johnson
IR Services, LLC, Tel: 860 434 2465
E-mail: jdjohnson@corpirservices.com
        ----------------------------